Praise the Lord! Jane’s biopsy was positive for the mutation EGFR T790M, the feature which allows the new drug Osimertinib to be used. Today Janet had a chest x-ray, ECG, and blood tests, before being prescribed this treatment, which is so costly it is only available under the special NHS Cancer Drugs Fund.

The side-effect profile is similar to that of Afatinib, Janet’s initial treatment, which became ineffective, and is mainly bowel and skin problems, which we can live with!

So we are hoping for a substantial period of progression-free health for Janet, one recent study showing 18 months median progression-free survival. Amen!